País: Irlanda
Idioma: inglés
Fuente: HPRA (Health Products Regulatory Authority)
PROCAINE BENZYLPENICILLIN
Norbrook Laboratories Limited
QJ01CE09
PROCAINE BENZYLPENICILLIN
300 Mg/Ml
Suspension for Injection
POM
Bovine, Porcine
Procaine penicillin
Antibacterial
Authorised
1997-12-12
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Ultrapen LA 300 mg/ml Suspension for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Suspension for injection. A white to off-white suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle and pigs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Ultrapen LA is specifically formulated to provide sustained antibacterial activity following a single administration. Ultrapen LA is indicated for use in cattle and pigs in the treatment and control of a wide range of common systemic, respiratory, urinary and local infections caused by or associated with organisms sensitive to penicillin, including _Corynebacterium pyogenes_, _Erysipelothrix rhusiopathiae_, _Pasteurella haemolytica_, _Pasteurella multocida_, _Staphylococcus _spp. (non-penicillinase producing) and _Streptococcus _spp. Ultrapen LA will therefore be effective in the treatment of infections, caused by susceptible organisms including: Erysipelas; navel/joint-ill; respiratory tract infections, including pneumonia and atrophic rhinitis; meningitis; septicaemia; toxaemia associated with mastitis; urogenital tract infections and the control of secondary bacterial invaders in diseases primarily of viral origin. 4.3 CONTRAINDICATIONS Do not administer by the intravenous route. Do not use on very small herbivores such as guinea pigs, gerbils and hamsters. Do not use in animals with known hypersensitivity to the active ingredient. Each ml contains: ACTIVE SUBSTANCE: Procaine Benzylpenicillin 300 mg EXCIPIENTS: Butylhydroxyanisole (E320) 0.1 mg Butylhydroxytoluene (E321) 0.1 mg HEALTH PRODUCTS REGULATORY AUTHORITY _________________________________________________________________________________________________________ Leer el documento completo